Survival benefit of gefitinib treated non-small-cell lung cancer patients with exon 19 deletion mutations in epidermal growth factor receptor (EGFR), detected by a new sensitive PCR-based method

E. Nakajima,Michio Sugita,Rafal Dziadziuszko,Masahiro Tsuboi,Harubumi Kato,Paul A. Bunn,Wilbur A. Franklin,Fred R. Hirsch

Survival benefit of gefitinib treated non-small-cell lung cancer patients with exon 19 deletion mutations in epidermal growth factor receptor (EGFR), detected by a new sensitive PCR-based method

2007

E. Nakajima
Michio Sugita
Rafal Dziadziuszko
Masahiro Tsuboi
Harubumi Kato
Paul A. Bunn
Wilbur A. Franklin
Fred R. Hirsch

10614 Background: As for two common types of EGFR mutations, patients with exon 19 deletion mutations have longer survival than those with the L858R point mutations in exon 21 after treatment with ...

Keywords:

Cell
Exon
Epidermal growth factor receptor
Cancer research
Lung cancer
Gefitinib
Molecular biology
Biology
deletion mutation
non small cell
Point mutation
Medicine
survival benefit

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations